View short and long-term study designs
Safety and tolerability were assessed in three 5-week randomized, double-blind, placebo-controlled studies. EMERGENT-2 (N=252) and EMERGENT-3 (N=256) were phase 3 trials and EMERGENT-1 (N=182 was a phase 2 trial. Long-term safety and tolerability were assessed in two 52-week, phase 3, open-label studies; EMERGENT-4 (n=152), an extension of EMERGENT-2 and EMERGENT-3, and EMERGENT-5 (n=566).1 See additional study design details.